Translational and Molecular Cytoarchitectural Genetic Guided Therapy to Induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and Associated Drug and Behavioral Addiction Seeking: A 60 Year Sojourn the Future is Now.
作者信息
Blum Kenneth, Badgaiyan Rajendra D
机构信息
Graduate College, Western University Health Sciences, Pomona, CA, USA.
Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital and Long School of Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
出版信息
EC Psychol Psychiatr. 2021 Jul 29;10(8):1-4.
Abstract
摘要
相似文献
1
2
Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
J Neurol Sci. 2020 Apr 15;411:116733. doi: 10.1016/j.jns.2020.116733. Epub 2020 Feb 14.
3
Chemogenetic Manipulations of Ventral Tegmental Area Dopamine Neurons Reveal Multifaceted Roles in Cocaine Abuse.
J Neurosci. 2019 Jan 16;39(3):503-518. doi: 10.1523/JNEUROSCI.0537-18.2018. Epub 2018 Nov 16.
4
Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.
Int J Environ Res Public Health. 2021 Nov 2;18(21):11529. doi: 10.3390/ijerph182111529.
5
Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.
J Addict Res Ther. 2012 Nov 27;3(5):139. doi: 10.4172/2155-6105.1000139.
6
Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction.
J Reward Defic Syndr. 2015;1(3):95-104. doi: 10.17756/jrds.2015-016. Epub 2015 Oct 23.
7
Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery.
J Genet Syndr Gene Ther. 2011 Dec 23;2012(1). doi: 10.4172/2157-7412.S2-001.
8
Addiction and brain reward and antireward pathways.
Adv Psychosom Med. 2011;30:22-60. doi: 10.1159/000324065. Epub 2011 Apr 19.
9
Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.
Med Hypotheses. 2011 Apr;76(4):576-84. doi: 10.1016/j.mehy.2011.01.005.
10
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.
Pharmacol Rev. 2021 Jan;73(1):163-201. doi: 10.1124/pharmrev.120.000083.
引用本文的文献
1
Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.
J Addict Psychiatry. 2024 Apr 5;8(1):1-33.
2
Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis.
Med Res Arch. 2023 Sep 14;11(8). doi: 10.18103/mra.v11i8.4211.
3
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids.
J Pers Med. 2022 Dec 6;12(12):2015. doi: 10.3390/jpm12122015.
4
GIRK Channels as Candidate Targets for the Treatment of Substance Use Disorders.
Biomedicines. 2022 Oct 13;10(10):2552. doi: 10.3390/biomedicines10102552.
本文引用的文献
1
Bariatric surgery: Potential post-operative heightened sensitivity to substances or behaviors.
J Syst Integr Neurosci. 2021 Mar 19;8:1.
2
Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions.
Nat Neurosci. 2021 Jul;24(7):954-963. doi: 10.1038/s41593-021-00860-2. Epub 2021 May 27.
3
Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis.
Front Psychiatry. 2021 Mar 30;12:623403. doi: 10.3389/fpsyt.2021.623403. eCollection 2021.
4
High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.
Mol Neurobiol. 2021 Jul;58(7):3335-3346. doi: 10.1007/s12035-021-02312-1. Epub 2021 Mar 8.
5
Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
J Syst Integr Neurosci. 2020 Aug;6(2). doi: 10.15761/JSIN.1000221. Epub 2019 Dec 19.
6
Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch.
J Neurol Sci. 2021 Jan 15;420:117252. doi: 10.1016/j.jns.2020.117252. Epub 2020 Nov 28.
7
Americas' opioid/psychostimulant epidemic would benefit from general population early identification of genetic addiction risk especially in children of alcoholics (COAs).
J Syst Integr Neurosci. 2019 Oct 31;5(2):1-3.
8
Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair.
Curr Pharm Biotechnol. 2020;21(6):528-541. doi: 10.2174/1389201021666191210112108.
9
Mechanisms of Persistent Neurobiological Changes Following Adolescent Alcohol Exposure: NADIA Consortium Findings.
Alcohol Clin Exp Res. 2019 Sep;43(9):1806-1822. doi: 10.1111/acer.14154. Epub 2019 Aug 14.
10
Genetic Addiction Risk Score (GARS) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis.
Curr Trends Med Diagn Methods. 2018;1(1). doi: 10.29011/CTMDM-101.100001. Epub 2018 Sep 11.
Zotero 插件